Financial Survey: FitLife Brands (NASDAQ:FTLF) versus Mind Medicine (MindMed) (NASDAQ:MNMD)

FitLife Brands (NASDAQ:FTLF) and Mind Medicine (MindMed) (NASDAQ:MNMD) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, risk, profitability, valuation and earnings.

Valuation & Earnings

This table compares FitLife Brands and Mind Medicine (MindMed)”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FitLife Brands	$52.70 million	2.82	$5.30 million	$1.69	19.11
Mind Medicine (MindMed)	N/A	N/A	-$95.73 million	($2.26)	-3.35

FitLife Brands has higher revenue and earnings than Mind Medicine (MindMed). Mind Medicine (MindMed) is trading at a lower price-to-earnings ratio than FitLife Brands, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares FitLife Brands and Mind Medicine (MindMed)’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
FitLife Brands	13.38%	28.03%	15.13%
Mind Medicine (MindMed)	N/A	-47.56%	-35.55%

Institutional and Insider Ownership

2.3% of FitLife Brands shares are held by institutional investors. Comparatively, 27.9% of Mind Medicine (MindMed) shares are held by institutional investors. 61.3% of FitLife Brands shares are held by insiders. Comparatively, 2.3% of Mind Medicine (MindMed) shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

FitLife Brands has a beta of 1.01, meaning that its stock price is 1% more volatile than the S&P 500. Comparatively, Mind Medicine (MindMed) has a beta of 2.48, meaning that its stock price is 148% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for FitLife Brands and Mind Medicine (MindMed), as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FitLife Brands	0	0	1	1	3.50
Mind Medicine (MindMed)	0	0	9	3	3.25

FitLife Brands presently has a consensus target price of $40.00, suggesting a potential upside of 23.84%. Mind Medicine (MindMed) has a consensus target price of $25.38, suggesting a potential upside of 235.65%. Given Mind Medicine (MindMed)’s higher probable upside, analysts clearly believe Mind Medicine (MindMed) is more favorable than FitLife Brands.

Summary

FitLife Brands beats Mind Medicine (MindMed) on 9 of the 14 factors compared between the two stocks.

About FitLife Brands

FitLife Brands, Inc. provides nutritional supplements for health-conscious consumers in the United States and internationally. The company provides weight loss, sports nutrition, and general health products; sports nutrition products; weight loss and sports nutrition products; sports nutrition and general wellness formulations with an emphasis on natural, vegan, and organic ingredients; and male health and weight loss products, as well as other diet, health, and sports nutrition supplements and related products; and value-oriented sports nutrition and weight loss products. It offers MRC products which includes general health supplements; and natural skincare and beauty products. In addition, it markets its products under the brand names of NDS Nutrition, PMD Sports, SirenLabs, CoreActive, Nutrology, Metis Nutrition, iSatori, BioGenetic Laboratories, Energize, Dr. Tobias, All-Natural Advice, and Maritime Naturals through franchised stores, as well as through retail locations, which include specialty, mass, and online. The company was formerly known as Bond Laboratories, Inc. and changed its name to FitLife Brands, Inc. in September 2013. FitLife Brands, Inc. was incorporated in 2005 and is headquartered in Omaha, Nebraska.

About Mind Medicine (MindMed)

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.